Scott E Hadland1, Victoria A Jent2, Rachel H Alinsky3, Brandon D L Marshall4, Pia M Mauro5, Magdalena Cerdá2. 1. Department of Pediatrics/Grayken Center for Addiction, Boston Medical Center, Boston, Massachusetts; Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts. Electronic address: scott.hadland@bmc.org. 2. Center for Opioid Epidemiology and Policy, Department of Population Health, New York University School of Medicine, New York, New York. 3. Division of General Pediatrics and Adolescent Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. 4. Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island. 5. Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York.
Abstract
INTRODUCTION: Special populations, including veterans, pregnant and postpartum women, and adolescents, benefit from opioid use disorder treatment tailored to their specific needs, but access to such services is poorly described. This study identifies the availability of opioid use disorder treatment facilities that use medications and have special programming and contextualizes facilities amid counties' opioid-related overdose mortality. METHODS: Data were compiled on 15,945 U.S. treatment facilities using medications for opioid use disorder listed in the Behavioral Health Services Treatment Locator in 2018. Facilities with programs tailored to special populations (veterans, pregnant and postpartum women, and adolescents) were identified and geocoded. Counties with such facilities were characterized. Cold spots (county clusters with poor treatment availability) were identified using Getis-Ord Gi* statistics. Data were extracted in October 2018 and analyzed from October 2018 to May 2019. RESULTS: Of all 3,142 U.S. counties, 1,889 (60.1%) had opioid use disorder treatment facilities. Facilities with tailored programs for veterans, pregnant and postpartum women, and adolescents were located in 701 (22.3%), 918 (29.2%), and 1,062 (33.8%) of the counties, respectively. Specific medications provided for opioid use disorder varied, with only a minority of facilities offering methadone (among facilities with tailored programs for veterans, 6.0%; pregnant and postpartum women, 13.2%; adolescents, 1.3%). Many counties reporting opioid-related overdose deaths lacked programs for special populations (veterans, 72.6%; pregnant and postpartum women, 54.8%; adolescents, 30.6%). Cold spots were located throughout the Midwest, U.S. Southeast, and portions of Texas. CONCLUSIONS: Facilities using medications for opioid use disorder with tailored programs for veterans, pregnant and postpartum women, and adolescents are limited. There is a need for improved access to evidence-based programs that address the unique treatment needs of special populations.
INTRODUCTION: Special populations, including veterans, pregnant and postpartum women, and adolescents, benefit from opioid use disorder treatment tailored to their specific needs, but access to such services is poorly described. This study identifies the availability of opioid use disorder treatment facilities that use medications and have special programming and contextualizes facilities amid counties' opioid-related overdosemortality. METHODS: Data were compiled on 15,945 U.S. treatment facilities using medications for opioid use disorder listed in the Behavioral Health Services Treatment Locator in 2018. Facilities with programs tailored to special populations (veterans, pregnant and postpartum women, and adolescents) were identified and geocoded. Counties with such facilities were characterized. Cold spots (county clusters with poor treatment availability) were identified using Getis-Ord Gi* statistics. Data were extracted in October 2018 and analyzed from October 2018 to May 2019. RESULTS: Of all 3,142 U.S. counties, 1,889 (60.1%) had opioid use disorder treatment facilities. Facilities with tailored programs for veterans, pregnant and postpartum women, and adolescents were located in 701 (22.3%), 918 (29.2%), and 1,062 (33.8%) of the counties, respectively. Specific medications provided for opioid use disorder varied, with only a minority of facilities offering methadone (among facilities with tailored programs for veterans, 6.0%; pregnant and postpartum women, 13.2%; adolescents, 1.3%). Many counties reporting opioid-related overdose deaths lacked programs for special populations (veterans, 72.6%; pregnant and postpartum women, 54.8%; adolescents, 30.6%). Cold spots were located throughout the Midwest, U.S. Southeast, and portions of Texas. CONCLUSIONS: Facilities using medications for opioid use disorder with tailored programs for veterans, pregnant and postpartum women, and adolescents are limited. There is a need for improved access to evidence-based programs that address the unique treatment needs of special populations.
Authors: Helen Valenstein-Mah; Hildi Hagedorn; Chad L Kay; Melissa L Christopher; Adam J Gordon Journal: Subst Abus Date: 2018-10-16 Impact factor: 3.716
Authors: Marian Jarlenski; Caroline Hogan; Debra L Bogen; Judy C Chang; Lisa M Bodnar; Elizabeth Van Nostrand Journal: Womens Health Issues Date: 2017-01-24
Authors: Scott E Hadland; Sarah M Bagley; Jonathan Rodean; Michael Silverstein; Sharon Levy; Marc R Larochelle; Jeffrey H Samet; Bonnie T Zima Journal: JAMA Pediatr Date: 2018-11-01 Impact factor: 16.193
Authors: Stephen W Patrick; Melinda B Buntin; Peter R Martin; Theresa A Scott; William Dupont; Michael Richards; William O Cooper Journal: Subst Abus Date: 2018-10-09 Impact factor: 3.984
Authors: Caitlin E Martin; Anna Beth Parlier-Ahmad; Lori Beck; Anna Scialli; Mishka Terplan Journal: Public Health Rep Date: 2021-09-21 Impact factor: 3.117
Authors: Tarlise Townsend; David Kline; Ariadne Rivera-Aguirre; Amanda M Bunting; Pia M Mauro; Brandon D L Marshall; Silvia S Martins; Magdalena Cerdá Journal: Am J Epidemiol Date: 2022-03-24 Impact factor: 5.363